Pneumococcal 23 Immunization
Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged ≥2 years with underlying medical conditions:
1. Children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia.
2. Immunocompetent children with chronic illness.
PPSV23 - 23-valent Pneumococcal Polysaccharide Vaccine
PCV13 - 13-valent Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine
Purified pneumococcal polysaccharide (23 types)
Not effective in children younger than 2 years
60%–70% against invasive disease
Less effective in preventing pneumococcal pneumonia
Pneumococcal Conjugate Vaccine
More than 90% effective against invasive disease caused by vaccine serotypes in children
45% effective against vaccine-type non-bacteremic pneumococcal pneumonia in adults older than 65 years
75% effective against vaccine- type invasive disease in adults older than 65 years